Evidence map›Paper›PMID 36228014›Full record

ArticlePloS one2022

A low rate of end-stage kidney disease in membranous nephropathy: A single centre study over 2 decades.

Joshua Storrar, Tarra Gill-Taylor, Rajkumar Chinnadurai, Constantina Chrysochou, Dimitrios Poulikakos, Francesco Rainone, James Ritchie, Elizabeth Lamerton, Philip A Kalra, Smeeta Sinha

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Joshua StorrarSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.ORCID 0000-0001-8377-9336
Tarra Gill-TaylorSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
Rajkumar ChinnaduraiSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
Constantina ChrysochouSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
Dimitrios PoulikakosSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
Francesco RainoneSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
James RitchieSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
Elizabeth LamertonSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
Philip A KalraSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
Smeeta SinhaSalford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.
Salford Royal Hospital · GBUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMembranous nephropathy is the commonest cause of nephrotic syndrome in non-diabetic Caucasian adults over the age of 40 years. Primary membranous nephropathy is limited to the kidneys. Clinical management aims to induce remission, either spontaneously with supportive care, or with immunosuppression. Here, we describe the natural history of this condition in a large tertiary centre in the UK.

methods178 patients with primary membranous nephropathy were identified over 2 decades. We collected data on demographics, baseline laboratory values, treatment received and outcomes including progression to renal replacement therapy and death. Analysis was performed on the whole cohort and specific subgroups. Univariate and multivariate Cox regression was also performed.

resultsMedian age was 58.3 years with 63.5% male. Median baseline creatinine was 90μmol/L and urine protein-creatinine ratio 664g/mol. Remission (partial or complete) was achieved in 134 (75.3%), either spontaneous in 60 (33.7%) or after treatment with immunosuppression in 74 (41.6%), and of these 57 (42.5%) relapsed. Progression to renal replacement therapy was seen in 10.1% (much lower than classically reported) with mortality in 29.8%. Amongst the whole cohort, those who went into remission had improved outcomes compared to those who did not go into remission (less progression to renal replacement therapy [4.5% vs 28%] and death [20.1% vs 67%]. Those classified as high-risk (based on parameters including eGFR, proteinuria, serum albumin, PLA2R antibody level, rate of renal function decline) also had worse outcomes than those at low-risk (mortality seen in 52.6% vs 10.8%, p<0.001). The median follow-up period was 59.5 months.

conclusionWe provide a comprehensive epidemiologic analysis of primary membranous nephropathy at a large tertiary UK centre. Only 10.1% progressed to renal replacement therapy. For novelty, the KDIGO risk classification was linked to outcomes, highlighting the utility of this classification system for identifying patients most likely to progress.

Indexed as

Glomerulonephritis, MembranousKidney Failure, ChronicCreatinineFemaleHumansImmunosuppressive AgentsMaleMiddle AgedSerum AlbuminCreatinineImmunosuppressive AgentsSerum Albumin

Identifiers

PMID36228014
PMCPMC9560622
OpenAlexW4305040592

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.